Anna T. Conley
University of Maryland, Baltimore
4 Papers
Anna T. Conley is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Interquartile range & Bacteremia. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Comparing the Outcomes of Adults With Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort.
Darunee Chotiprasitsakul,Jennifer H. Han,Sara E. Cosgrove,Anthony D. Harris,Ebbing Lautenbach,Anna T. Conley,Pam Tolomeo,Jacqueleen Wise,Pranita D. Tamma +8 more
TL;DR: Short courses of antibiotics therapy yield similar clinical outcomes as prolonged courses of antibiotic therapy for Enterobacteriaceae bacteremia, and may protect against subsequent MDRGN bacteria.
162
Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.
Pranita D. Tamma,Anna T. Conley,Sara E. Cosgrove,Anthony D. Harris,Ebbing Lautenbach,Joe Amoah,Edina Avdic,Pam Tolomeo,Jacqueleen Wise,Sonia Subudhi,Jennifer H. Han +10 more
TL;DR: The findings suggest that transitioning to oral step-down therapy may be an effective treatment approach for patients with Enterobacteriaceae bacteremia who have received source control and demonstrated an appropriate clinical response.
A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis.
TL;DR: It is suggested that decreasing the duration of antibiotic therapy for pyelonephritis may impact a large number of women, and 7 days of TMP-SMX therapy may result in similar clinical outcomes compared with 6 days of ciprofloxacin.
21
Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma.
TL;DR: A case of glutamic acid decarboxylase antibody-positive type 1 diabetes developing in a patient with a long-standing history of well-controlled type 2 diabetes following treatment with atezolizumab for metastatic renal cell carcinoma is presented.